Last reviewed · How we verify

Placebo matching dostarlimab

Tesaro, Inc. · Phase 3 active Small molecule

Placebo matching dostarlimab is a PD-1 inhibitor Small molecule drug developed by Tesaro, Inc.. It is currently in Phase 3 development for Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer, Recurrent or advanced endometrial cancer.

Dostarlimab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2) on tumor cells, thereby releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer cells.

Dostarlimab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2) on tumor cells, thereby releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer cells. Used for Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer, Recurrent or advanced endometrial cancer.

At a glance

Generic namePlacebo matching dostarlimab
SponsorTesaro, Inc.
Drug classPD-1 inhibitor
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Dostarlimab binds to programmed death receptor 1 (PD-1) on the surface of T lymphocytes, preventing engagement with PD-L1 and PD-L2 expressed on tumor and antigen-presenting cells. This blockade restores T cell activation, proliferation, and effector functions, enabling the immune system to mount an anti-tumor response. The drug is administered intravenously and has demonstrated clinical activity across multiple cancer types, particularly those with mismatch repair deficiency or high microsatellite instability.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo matching dostarlimab

What is Placebo matching dostarlimab?

Placebo matching dostarlimab is a PD-1 inhibitor drug developed by Tesaro, Inc., indicated for Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer, Recurrent or advanced endometrial cancer.

How does Placebo matching dostarlimab work?

Dostarlimab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2) on tumor cells, thereby releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer cells.

What is Placebo matching dostarlimab used for?

Placebo matching dostarlimab is indicated for Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer, Recurrent or advanced endometrial cancer.

Who makes Placebo matching dostarlimab?

Placebo matching dostarlimab is developed by Tesaro, Inc. (see full Tesaro, Inc. pipeline at /company/tesaro-inc).

What drug class is Placebo matching dostarlimab in?

Placebo matching dostarlimab belongs to the PD-1 inhibitor class. See all PD-1 inhibitor drugs at /class/pd-1-inhibitor.

What development phase is Placebo matching dostarlimab in?

Placebo matching dostarlimab is in Phase 3.

What are the side effects of Placebo matching dostarlimab?

Common side effects of Placebo matching dostarlimab include Fatigue, Diarrhea, Nausea, Anemia, Immune-mediated colitis, Pneumonitis.

What does Placebo matching dostarlimab target?

Placebo matching dostarlimab targets PD-1 and is a PD-1 inhibitor.

Related